Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients

By Bighin Claudia   Pronzato Paolo   Del Mastro Lucia  

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 955-957

Future Medicine

Access to resources Recommend Favorite

Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer

By Osako Tomo   Ito Yoshinori   Takahashi Shunji   Tokudome Nahomi   Iwase Takuji   Hatake Kiyohiko  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 159-164

Springer Publishing Company

Access to resources Recommend Favorite

Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab

By                  

International Journal of Oncology, Vol. 41, Iss. 4, 2012-01 ,pp. : 1204-1212

Spandidos Publications

Access to resources Recommend Favorite

Continued Use of Trastuzumab (Herceptin) after Progression on Prior Trastuzumab Therapy in HER-2-Positive Metastatic Breast Cancer

By Pusztai Lajos   Esteva Francisco  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 187-191

Informa Healthcare

Access to resources Recommend Favorite

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer

By Modi Shanu  

Breast Cancer Research and Treatment, Vol. 139, Iss. 1, 2013-05 ,pp. : 107-113

Springer Publishing Company

Access to resources Recommend Favorite